Psylink, a Vilnius-based startup targeted on creating progressive remedies for individuals dealing with psychological well being challenges, raised over €500k in a pre-Seed funding spherical.
The spherical was led by the VC fund Coinvest Capital, with Firstpick and BSV additionally collaborating, together with a syndicate of angel buyers.
“At Psylink, we’re creating science-based therapies impressed by nature to assist those that haven’t benefited from typical remedies. We’re proud to companion with buyers who recognise the urgency and potential of this work. Our multidisciplinary workforce is united by a transparent mission: to create protected, efficient, and sustainable options for psychological well being, drawing on the wealthy range of bioactive compounds present in vegetation and fungi,” stated Laura Korsakova, CEO of Psylink.
Based in 2020, Psylink is a BioTech firm targeted on creating progressive remedies for psychological well being problems. Its R&D technique is constructed on two key pillars. Psylink is creating a sustainable biotechnology platform to supply pure compounds, significantly fungi-derived molecules, utilizing engineered yeast cells as biosynthetic “mini-factories.” This methodology goals to supply an environmentally pleasant various to conventional chemical synthesis and extraction processes.
The second pillar focuses on discovering and evaluating novel compounds for situations like despair and PTSD. By learning psilocybin and associated fungal metabolites, Psylink goals to uncover new therapeutic brokers by a deeper understanding of their molecular interactions and results on mobile programs.
“Psylink stands out by combining rigorous biotechnology with the therapeutic potential of pure compounds – an method that’s not solely progressive but in addition grounded in sturdy scientific validation. What impressed us is their means to bridge conventional knowledge and fashionable neuroscience. That is precisely the form of transformative innovation the psychological healthcare market urgently wants, and we imagine Psylink is well-positioned to steer on this rising house,” Viktorija Trimbel, Managing Director of Coinvest Capital, famous.
The capital might be used to advance Psylink’s proprietary biotechnology platform for the sustainable manufacturing of plant- and fungi-derived compounds. It’ll additionally gas the screening and analysis of novel molecular candidates, accelerating the identification of high-potential compounds for additional growth and preclinical validation.
“Psylink’s work with next-generation psychedelic derivatives has the potential to redefine what’s potential for sufferers dealing with psychological well being challenges. I’m honored to assist the workforce at this early stage and to assist deliver these much-needed therapies nearer to those that want them most,” stated Erin Gainer, lead of the angel investor syndicate.
Psylink outlines that they had been established to handle a vital hole within the psychological healthcare market by creating novel remedies for sufferers who don’t reply to standard therapies.
With an estimated 30–40% of people with despair experiencing minimal or no profit from normal antidepressants, there’s a demand for simpler, science-driven options – an space Psylink goals to steer.
“Psylink is a uncommon instance of DeepTech innovation from our area, addressing a worldwide problem with scientific readability and function. We’re proud to assist a workforce creating actual BioTech with the potential to rework how we deal with psychological well being,” commented Sandra Golbreich, Accomplice at BSV Ventures.
